A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not ...

COPENHAGEN, Denmark I September 16, 2024 I Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing ...

One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.

1 The trial (NCT05499390) included patients with previously untreated, PD-L1 positive, stage IIIB-IV NSCLC. The patients received the PD-1/VEGF bispecific antibody ivonescimab (n=198) or pembrolizumab ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will highlight new data from across its approved and investigational cancer therapies during the 2024 European Society ...

Ivonescimab improved PFS when compared to pembrolizumab as first-line therapy in patients with advanced NSCLC in the phase 3 HARMONi-2 trial.

ChromaDex Corp. , the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, is excited to announce the second wave of intravenous (IV) wellness clinics ...

At WCLC, five-year survival data to be presented on Libtayo (PD-1 inhibitor) first-line monotherapy in advanced non-small cell lung cancer At ESMO, longer-term results with investigational fianlimab ...

The therapeutic landscape for non–small cell lung cancer (NSCLC) has been relatively stable since the 2016 approval of ...

VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced ...

2 Similarly, the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) resulted in an ORR of 54% and a median PFS of 17.4 months. 3 “In terms of overall survival [OS], we are also seeing a ...

NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit up to 100 people. Looking back over the journey from our humble beginnings ...